Cost-effectiveness of repeated aphereses in poor mobilizers undergoing high-dose chemotherapy and autologous hematopoietic cell transplantation.
Chabannon
C
C
Le Corroller
A-G
AG
Viret
F
F
Eillen
C
C
Faucher
C
C
Moatti
J-P
JP
Viens
P
P
Vey
N
N
Braud
A-C
AC
Novakovitch
G
G
Ladaique
P
P
Stoppa
A-M
AM
Camerlo
J
J
Genre
D
D
Maraninchi
D
D
Blaise
D
D
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001772:Blood Cell Count; D001781:Blood Component Removal / Q000191:economics*; D015331:Cohort Studies; D003131:Combined Modality Therapy; D003362:Cost-Benefit Analysis; D005260:Female; D000069585:Filgrastim; D006085:Graft Survival; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology; D019650:Hematopoietic Stem Cell Mobilization / Q000191:economics* / Q000379:methods; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy / Q000628:therapy; D036102:Peripheral Blood Stem Cell Transplantation / Q000191:economics*; D011994:Recombinant Proteins; D012189:Retrospective Studies; D014182:Transplantation, Autologous
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000069585:Filgrastim